I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on March 9, 2007.

Frank C. Eisenschenk, Ph.D., Patent Attorney

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Patent Application

Docket No. ARS-124 Serial No. 10/573,625

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Amanda Proudfoot, Jeffrey Shaw, Zoe Johnson

Serial No. : 10/573,625

Filed: March 28, 2006

Conf. No. : 9024

For : Therapeutic Uses of Chemokine Variants

Mail Stop PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the reference listed on the attached form PTO/SB/08 is being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. A copy of the cited reference is enclosed. Applicants note that there was an oral presentation related to the reference enclosed herein on November 28, 2003.

It is respectfully requested that the reference cited on the attached form PTO/SB/08 be considered in the examination of the subject application and that its consideration be made of record.

Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100 Fax No.: 352-372-5800 Address: P.O. Box 142950

Gainesville, FL 32614-2950

FCE/sl

Attachments: Form PTO/SB/08; copy of cited reference

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

	Substitute for form 1449B/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT					Application Number	10/573,625		
					Filing Date March 28, 2006			
					First Named Inventor	Amanda Proudfoot		
	(n	eede vaam ea ee	te ae nei	rescenti	Group Art Unit			
(use as many sheets as necessary)					Examiner Name			
	Sheet	1	of	1	Attorney Docket Number	ARS-124		

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²				
		JOHNSON, Z. "The Role of Glycosaminoglycan Binding and Oligomerisation in Chemokine Function in Vivo", thesis catalogued on July 13, 2004 in the Senate House Library,					
	R1	University of London, pp 1-273.					
	R2						
	R3						
	R4						
	R5						
	R6						
	R 7						
	R8						
	R9						
	R10						
VV. V. A. A.	N IU						
·	R11						
	R12						
	R13						

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.